RxDoctor Payments Data

William Schneider, MD

Forensic Psychiatry · Villa Rica, GANPI 1023273109

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $14,285 of the $19,621 with a category attached, or 72.8%. Otsuka America Pharmaceutical, Inc. accounts for 79.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $7,944 and has fallen 80.3% since, to $1,564 in 2025.

$19,621in general payments, 2019–2025

Across 206 payments — averaging $95.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$15K
  • Alkermes, Inc.$834
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$652
  • Neurocrine Biosciences, Inc.$496
  • AbbVie$403
  • Supernus Pharmaceuticals, Inc.$357
  • plus $1K from 13 others

What the payments were for

  • Speaking & faculty fees$14,28573%
  • Travel & lodging$6473%
  • Food & beverage$4,63924%
  • Education$500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few forensic psychiatry providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$40,491
Medicare patients
56
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate11$38,342
Lurasidone Hcl92$13,097
Aripiprazole73$5,355
Ziprasidone Hcl63$3,362
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl29$2,869
Mirtazapine113$1,797
Oxcarbazepine46$1,544
Quetiapine Fumarate115$1,449
Clozapine12$1,112
Olanzapine57$1,086
Haloperidol Decanoate16$1,075
Trazodone Hcl123$872
Clonazepam228$854
Gabapentin61$811
Duloxetine Hcl73$780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$190$38,34211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few forensic psychiatry providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other forensic psychiatry in Villa Rica

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →